This study is designed to look at minocycline versus a placebo in the treatment of HIV infected people with cognitive impairment. Eligible individuals will receive the study drug or placebo for 24 weeks. Participants who are able to remain on study treatment through week 24 will be given the option to enter Step 2 and receive open-label minocycline for 24 weeks.

Inclusion Criteria:

• Men and women between the ages of 18 and 65 years
• Documented HIV infection
• On stable antiretroviral therapy for 16 weeks prior to study entry and willing to remain on stable therapy through week 24 of the study
• AIDS dementia scale greater than Stage 0
• Cognitive impairment as defined during screening
• Willingness to have multiple lumbar punctures (spinal taps) as per protocol

Exclusion criteria:

• Currently pregnant or breastfeeding
• Unwillingness to use at least two forms of birth control if of reproductive ability
• Any serious infection, cancer or AIDS defining illnesses within 45 days of study entry
• Severe psychiatric illnesses. Those with active depression on a stable antidepressant for more than 16 weeks are eligible
• Systemic lupus

This study is being conducted by Dr. Elyse Singer under IRB #06-08-077-01

If you think you might be interested in participating in this study, please contact Blanca Corea at 310-557-9062 or email at bcorea@mednet.ucla.edu

Return to Clinical Trials main page